CR Bard Inc
Most Recent
BD Gets Final Regulatory Approval for Bard Acquisition
On December 28, Becton, Dickinson and Company (BDX), or BD, received clearance for its Bard (BCR) acquisition form MOFCOM (Ministry of Commerce of the People’s Republic of China), but the approval is contingent on the divestment of BD’s soft tissue core needle biopsy product line.
BD Stock Fell 2.7% on September 13: Should Investors Worry?
Becton, Dickinson and Company (BDX) closed at $196.62 on September 13, 2017.
Behind Baxter International’s Analyst Recommendations
Baxter International (BAX) released its 2Q17 earnings results on July 26, beating the analysts’ estimates for both revenues and earnings per share.
How Medtronic Is Delivering on Its Covidien Synergies
In January 2015, Medtronic (MDT) acquired Covidien for ~$43 billion in cash and MDT stock in a tax inversion deal.
Becton Dickinson’s Bard Acquisition: On Track, Gaining Momentum
Becton Dickinson (BDX) is set to complete another large acquisition of C.R. Bard (BCR) worth $24.0 billion in the fall of 2017.
A Brief Look at Dividend Aristocrats
The S&P 500 Dividend Aristocrat Index is made up of 51 S&P 500 (SPY) (SPX-INDEX) companies that have increased their dividends for 25 successive years.
Varian Medical Systems’ Recent Stock Performance
Stock performance Varian Medical Systems (VAR) closed at $96.20 on August 9, 2017. It has a 50-day moving average of $102.30, and a 200-day moving average of $93.20. On August 9, 2017, Varian stock was trading ~27% above its 52-week low of $75.90 on November 9, 2016, and ~10% below its 52-week high of $107.10 on […]
What Drove Varian to Revise Its Revenue Guidance
Company guidance Year-over-year, Varian Medical Systems (VAR) expects its 4Q17 revenue to be flat or fall. According to the company, headwinds from the euro, British pound, and Japanese yen are expected to have an impact of around $10 million, $12 million, and $15 million, respectively. The company’s diluted EPS (earnings per share) are expected to be […]
A Look at Varian Medical Systems’ Long-Term Goals
Varian Medical Systems’ long-term goals Varian Medical Systems (VAR) hopes to improve the lives of around 6 million cancer patients each year, which would double what the company has achieved to date. Varian is aiming for 5%–6% annual revenue growth, whereas its current 12-month trailing revenue growth is 3%. Varian aims to achieve a 22% return […]
How BDX Returns Value to Its Shareholders
BD announced a quarterly cash dividend of $0.73 per share on July 25, 2017.
What to Expect from Baxter International’s 2Q17 Earnings
In 1Q17, Baxter International exceeded analysts’ EPS estimate of $0.52 as well as the revenue estimate of ~$2.4 billion.
Discussing Baxter International’s 2Q17 Revenue Estimates
Wall Street analysts estimate that Baxter International’s 2Q17 revenues should come in at ~$2.6 billion, a rise of ~0.4% on a year-over-year basis. The company reported revenues of $2.5 billion in 1Q17.
What’s Does Wall Street Think of PPG Post-2Q17?
At present, 22 analysts are actively monitoring PPG Industries (PPG). Among these analysts, 63% have recommended “buys” on the stock.
Key Highlights of Varian Medical Systems’ Fiscal 2Q17 Earnings
On April 26, 2016, Varian Medical Systems (VAR) released its 2Q17 earnings. VAR beat consensus estimates for revenues in 2Q17 by ~0.8% and reported in-line earnings per share.
How BD-Bard Acquisition Will Strengthen International Presence
C.R. Bard (BCR) has grown significantly outside the United States in recent years, driven by its international channel expansion strategy.
How the BD-Bard Deal Will Create Shareholder Value
The BD-Bard acquisition is expected to create significant shareholder value since the two companies are believed to be a highly strategic fit.
C.R. Bard’s Business Profile and the BD-Bard Deal Rationale
Bard’s strong vascular and surgery product portfolio is expected to be highly complementary to BD’s CareFusion portfolio in international markets.
BD to Acquire C.R. Bard: Deal Highlights and Market Reaction
On April 23, 2017, Becton, Dickinson and Company (or BD) (BDX) announced it will acquire C.R. Bard (BCR) for $317 per Bard share, for a $24.0 billion cash and stock deal.
What to Expect from Baxter International’s 1Q17 Earnings
Baxter International (BAX) has exceeded analysts’ earnings estimates for the last few quarters.
Baxter’s Latest Dividend and Share Repurchase Authorization
Baxter International (BAX) announced a quarterly cash dividend of $0.13 per share on November 8, 2016.
Analysts’ Latest Recommendations for Baxter: Mostly ‘Holds’
Let’s look at Wall Street analysts’ recommendations and target prices for Baxter International (BAX) over the next 12 months.
Particle Therapy Business Witnessed Continued Growth Momentum in 4Q16
Varian Medical Systems (VAR) registered revenues of $68.2 million in 4Q16, of which 7.5% came from the company’s oncology segment.
Analysts Expect Flat Revenue for Baxter in 3Q16
Revenue estimates On October 25, 2016, Baxter International (BAX) will announce its fiscal 3Q16 earnings for the period ending September 30, 2016. Wall Street has estimated Baxter’s 3Q16 revenue to be about $2.55 billion, a marginal decline from last quarter’s revenue of ~$2.58 billion. Investors can gain exposure to Baxter by investing in the iShares Edge […]
Baxter International’s Latest Dividend Payment
Baxter International (BAX) announced a quarterly cash dividend of $0.13 per share on July 19, 2016.
Baxter International’s Recent Product Launches and Partnerships
Baxter International’s R&D investments were around $150 million in 2Q16, which represents a YoY (year-over-year) increase of around 1%.
How Has Baxter’s Stock Performed?
Baxter’s stock price has risen ~1.8% since the release of its 2Q16 results on July 26, 2016.
Vanguard Morgan Growth Fund’s Sector Composition in YTD 2016
Information technology is by far the biggest invested sector in the Vanguard Morgan Growth Fund (VMRGX), forming over a third of the total portfolio.
Varian Medical Systems Attempts to Improve Its Performance Growth
Varian Medical Systems (VAR) raised its guidance for fiscal 2016 in the view of higher-than-expected 3Q16 results reported on July 27.
Varian Medical Systems’ Oncology Devices Are Key to Sales Growth
Varian Medical Systems commands the majority share of the oncology device market in the United States.
What’s BSX’s Capital Allocation Strategy Going Forward?
In August 2015, BSX acquired American Medical Systems’ male urology business for $1.6 billion in cash and milestone-based payments of $50 million.
C.R. Bard’s Vascular Segment Flowing Well despite Tougher Comps
C.R. Bard (BCR) reported ~$931.5 million in total revenues in 2Q16. Of that, ~$255.3 million was contributed by the company’s Vascular business segment.
C.R. Bard Registered Strong 2Q16 Performance, Beat Estimates
On July 26, 2016, C.R. Bard (BCR) released its 2Q16 earnings. After the announcement, BCR’s share price rose by ~1%, driven by its better-than-expected 2Q16 results.
Baxter’s 2Q16 Profitability and 2016 Guidance
Baxter International’s adjusted operating margin came in at ~12.3% in 2Q16, driven by strategic business alignment, portfolio optimization, and cost containment measures.
How Is Varian Positioned in the Particle Therapy Business?
Varian Medical Systems (VAR) had gross orders value of $310 million in 2015.
What Do Analysts Recommend for Varian Medical Systems?
On June 28, 2016, Goldman Sachs gave Varian Medical Systems a one-year target price of $73, the lowest of all the target prices provided.
How Varian Is Addressing Existing Gaps in Cancer Treatment
Varian Medical Systems has a large number of initiatives to leverage the expansion opportunities in the oncology market.
How Does Varian Medical Systems Compare to Peers on Valuation?
On June 16, 2016, Varian Medical Systems (VAR) was trading at a forward PE (price-to-earnings) ratio of ~17.7x.
Mapping Varian Medical Systems’ Geographic Strategy
Varian Medical Systems (VAR) is a global medical device company that generates ~50% of its total revenues from North America and 26% and 24% of total revenues from Europe and Asia, respectively.
Growth Strategies Driving Varian Medical Systems’ Revenue
Varian Medical Systems has ventured into the proton therapy business and has a huge product pipeline in this area. The company generated approximately $300 million through its proton therapy business in 2015.
Varian Medical Systems’ Growth Potential in Radiation Oncology
Varian Medical Systems’ next big technology innovation will be high-definition radiotherapy, which is an intelligent treatment delivery system that aims to achieve 100% radiation exposure for the tumor.
Where Does Varian Medical Systems Get Most of Its Revenue?
Varian Medical Systems’ Imaging Components segment accounts for approximately 19% of the company’s total revenue. The segment reported a revenue decline of ~10% in 2015.
Varian Medical Systems: A Leading Oncology Device Manufacturer
Varian Medical Systems (VAR), headquartered in Palo Alto, California, is a leading radiation oncology treatment device and software manufacturer. It reported revenues of approximately $3.1 billion in 2015.
Delving into C. R. Bard’s Surgical Specialties Business Segment
C. R. Bard’s (BCR) Surgical Specialties segment contributes around 17% of the total revenues of the company.
A Look at C. R. Bard’s Oncology Business Segment
C. R. Bard’s (BCR) Oncology segment contributes around 27% of the total revenues of the company.
A Breakdown of C. R. Bard’s Urology Business Segment
C. R. Bard’s (BCR) Urology segment contributes around 25% of the company’s total revenues.
Dissecting C. R. Bard’s Vascular Business Segment
C. R. Bard’s (BCR) Vascular segment contributes around 28% of the company’s total revenues.
A Breakdown of C. R. Bard’s Business Segments
C. R. Bard (BCR) generates revenues from manufacturing, selling, and marketing medical devices in four business segments.
Company Overview: An Introduction to C. R. Bard
Headquartered in Murray Hill, New Jersey, C. R. Bard (BCR) is a leading medical technology company in the United States.
Company & Industry Overviews Why VMRGX’s Year-to-Date 2016 Has Been Lackluster
As of May 27, 2016, the Vanguard Morgan Growth Fund Investor Shares (VMRGX) had fallen by 0.7% YTD (year-to-date) in 2016.
Boston Scientific’s Inorganic Growth Strategy
In recent years, Boston Scientific (BSX) has grown significantly through expansion of its product portfolio and geographic reach, as well as the reorganization and cost containment measures.
